

# Retinal Diseases

---

*Ala Moshiri M.D. Ph.D.*  
*U.C. Davis Eye Center*

# Financial Disclosures


# Overview

- **Background Information**
- **Retinal Vascular Disease**
- **Age-Related Macular Degeneration**
- **Diabetic Retinopathy**
- **Questions from the Audience**


# Overview

- **Background Information**
- **Retinal Vascular Disease**
- **Age-Related Macular Degeneration**
- **Diabetic Retinopathy**
- **Questions from the Audience**


- The eye can only perceive a small portion of the spectrum of electromagnetic waves




# External Features and Accessory Structures of the Eye



# The Pupillary Muscles




# The Sectional Anatomy of the Eye






# Sectional Anatomy of the Eye





# The Circulation of Aqueous Humor




# Eye Abnormalities

## ➤ Glaucoma

## ➤ Cataract



# Image Formation




**(a) The closer the light source, the longer the focal distance**


**(b) The rounder the lens, the shorter the focal distance**

# Accommodation


- It is the process of adjusting the shape of the lens so that the external image fall exactly on the retina



# The Organization of the Retina





# Rods and Cones



# Retinal structure


## ➤ Three cell layers:

- outer layer: photoreceptors- rods and cones
- middle layer: bipolar neurons
- inner layer: ganglion cells






# The Organization of the Retina




(b)



(c)


# The Visual Pathways




# Overview

- Background Information
- **Retinal Vascular Disease**
- Age-Related Macular Degeneration
- Diabetic Retinopathy
- Questions from the Audience


# Central Retinal Artery Occlusion








# Central Retinal Vein Occlusion







# Overview

- Background Information
- Retinal Vascular Disease
- **Age-Related Macular Degeneration**
- Diabetic Retinopathy
- Questions from the Audience

# Overview

➤ **Dry AMD**

➤ **Wet AMD**

# Overview

- **Dry AMD**
- **Wet AMD**



# Vitamins for Dry AMD

## ➤ AREDS 2

- Vitamin C - 500 mg
- Vitamin E - 400 IU
- Beta-Carotene - 15 mg [AREDS2 is testing without this too]
- Zinc - 80 mg
- Copper - 2 mg
- Lutein - 10 mg
- Zeaxanthin - 2 mg
- DHA - 350 mg
- EPA - 650 mg





# Overview

- **Dry AMD**
- **Wet AMD**



# Molecular Pathogenesis of CNV






# Overview

- **Background Information**
- **Retinal Vascular Disease**
- **Age-Related Macular Degeneration**
- **Diabetic Retinopathy**
- **Questions from the Audience**



# Diabetic Retinopathy

---



- Diabetic retinopathy is the most common cause of new cases of blindness among adults 20-74 years of age.
- Each year, between 12,000 to 24,000 people lose their sight because of diabetes.
- During the first two decades of disease, nearly all patients with type 1 diabetes and over 60% of patients with type 2 diabetes have retinopathy

# Risks of Diabetic Retinopathy Related Vision Loss

---

## ➤ Duration of diabetes disease

- WESDR demonstrated that type 1 patients experience a 25% rate of retinopathy after 5 years of disease, and 80% at 15 years of disease<sup>1</sup>
- Up to 21% of newly diagnosed type 2 patients have some degree of retinopathy at time of diagnosis<sup>1</sup>

## ➤ Puberty

## ➤ Pregnancy


## ➤ Lack of appropriate ophthalmic examination

<sup>1</sup>American Diabetes Association: Retinopathy in Diabetes (Position Statement). *Diabetes Care* 27 (Suppl.1): S84-S87, 2004

# Retinopathy Screening

---

- **Type 1 diabetes - screen within 3-5 years of diagnosis after age 10<sup>1</sup>**
- **Type 2 diabetes - screen at time of diagnosis<sup>1</sup>**
- **Pregnancy - women with preexisting diabetes should be screened prior to conception and during first trimester<sup>1</sup>**
- **Follow-up annually; less frequent exams (2-3 yrs) may be considered<sup>1</sup>**
- **Examination Methods - Dilated indirect ophthalmoscopy coupled with biomicroscopy and seven-standard field stereoscopic 30° fundus photography<sup>1</sup>**



<sup>1</sup>American Diabetes Association: Retinopathy in Diabetes (Position Statement). *Diabetes Care* 27 (Suppl.1): S84-S87, 2004


# **CLINICAL CLASSIFICATION OF DIABETIC RETINOPATHY**

---

- **Background**
- **Pre-proliferative**
- **Proliferative**
- **End-stage diabetic eye disease**

# Natural History of Diabetic Retinopathy

---



- **Mild nonproliferative diabetic retinopathy (NPDR)**
- **Moderate NPDR**
- **Severe NPDR**
- **Very Severe NPDR**
- **Proliferative diabetic retinopathy (PDR)**

# Mild NPDR

---

## ➤ Clinical Findings

- Increased vascular permeability
- Microaneurysms
- Intraretinal hemorrhages
- Clinically Significant Macular Edema (CSME) possible

## ➤ Management/Treatment

- Annual follow-up
- If CSME present: color fundus photography, fluorescein angiography, and photocoagulation

# Moderate NPDR

---

## ➤ Clinical Findings

- Venous caliber changes
- Intraretinal Microvascular Abnormalities (IRMAs)
- CSME possible

## ➤ Management/Treatment

- 6-12 month follow-up without CSME
- Color fundus photography
- CSME present: color fundus photography, fluorescein angiography, focal photocoagulation, 3-4 month follow-up

# Severe/Very Severe NPDR

---

## ➤ Clinical Findings

- Retinal ischemia
- IRMAs
- Extensive hemorrhage and microaneurysms
- CSME possible

## ➤ Management/Treatment

- 3-4 month follow-up
- Color fundus photography
- Possible panretinal photocoagulation
- CSME present: color fundus photography, fluorescein angiography, focal photocoagulation, 3-4 month follow-up



# PDR

---

## ➤ Clinical Findings

- Ischemia induced neovascularization
  - at the optic disk (NVD)
  - elsewhere in the retina (NVE)
- Vitreous hemorrhage
- Retinal traction, tears, and detachment
- CSME possible

# PDR, cont.

---

## ➤ Management/Treatment


- 2-4 month follow-up
- Color fundus photography
- Panretinal photocoagulation (3-4 month follow-up)
- Vitrectomy
- CSME present: focal photocoagulation, fluorescein angiography

# Prevention of Diabetic Retinopathy Associated Vision Loss



---

- Intensive glycemic control
- Tight blood pressure control  
( $<130/80$  mmHg)
- Comprehensive eye  
examinations

# Pathogenesis of diabetic retinopathy




1. Basement membrane thickening
2. Endothelial cell damage
3. R.B.C. changes
4. Platelet stickiness increased




Loss of pericytes


# Consequences of retinal ischaemia



# Consequences of chronic leakage



# Location of lesions in background diabetic retinopathy



# Background

---





# Signs of background diabetic retinopathy



Microaneurysms usually temporal to fovea




Intraretinal dot and blot hemorrhages



Hard exudates frequently arranged in clumps or rings



Retinal edema seen as thickening on biomicroscopy




lipid exudate    intraretinal hemorrhages


(From Kaiser PK, Friedman NJ, Pineda R II: *Massachusetts Eye and Ear Infirmary Illustrated Manual of Ophthalmology*, 2nd ed, Philadelphia, Saunders, 2004.)

Elsevier items and derived items © 2005 by Elsevier Inc.


## Focal diabetic maculopathy



- Circumscribed retinal thickening
- Associated complete or incomplete circinate hard exudates



- Focal leakage on FA
- Focal photocoagulation
- Good prognosis



neovascularization

capillary nonperfusion


(From Kaiser PK, Friedman NJ, Pineda R II: *Massachusetts Eye and Ear Infirmary Illustrated Manual of Ophthalmology*, 2nd ed, Philadelphia, Saunders, 2004.)

Elsevier items and derived items © 2005 by Elsevier Inc.

## Diffuse diabetic maculopathy



- Diffuse retinal thickening
- Frequent cystoid macular edema
- Variable impairment of visual acuity



- Generalized leakage on FA
- Grid photocoagulation
- Guarded prognosis



# Diabetic maculopathy

---



Hard  
exudate

# Ischemic diabetic maculopathy




- Macula appears relatively normal
- Poor visual acuity

- Capillary non-perfusion on FA
- Treatment not appropriate

# Clinically significant macular edema

Retinal edema  
within 500  $\mu\text{m}$   
of centre of fovea



Hard exudates  
within 500  $\mu\text{m}$   
of centre of  
fovea with adjacent  
edema which may  
be outside 500  $\mu\text{m}$   
limit

Retinal edema one disc area or larger any  
part of which is within one disc diameter  
(1500  $\mu\text{m}$ ) of centre of fovea




# Treatment of clinically significant Macular edema

## Grid treatment



- For diffuse retinal thickening located more than 500  $\mu\text{m}$  from center of fovea and 500  $\mu\text{m}$  from temporal margin of disc
- Gentle burns (100-200  $\mu\text{m}$ , 0.10 sec), one burn width apart

## Focal treatment



- For microaneurysms in centre of hard exudate rings located 500-3000  $\mu\text{m}$  from center of fovea
- Gentle whitening or darkening of microaneurysm (100-200  $\mu\text{m}$ , 0.10 sec)

# Pre-proliferative

---



# Preproliferative diabetic retinopathy

## Signs



- Cotton-wool spots
- Venous irregularities



- Dark blot hemorrhages
- Intraretinal microvascular abnormalities (IRMA)


**Treatment** - not required but watch for proliferative disease

## Proliferative diabetic retinopathy

- Affects 5-10% of diabetics
- IDDM at increased risk (60% after 30 years)

### Neovascularization

- Flat or elevated
- Severity determined by comparing with area of disc





Neovascularization of disc = NVD



Neovascularization elsewhere = NVE

# Proliferative retinopathy






Pre-retinal haemorrhage





Laser burn scars


## Indications for treatment of proliferative diabetic retinopathy

		
NVD > 1/3 disc in area	Less extensive NVD + haemorrhage	NVE > 1/2 disc in area + haemorrhage

# Laser panretinal photocoagulation



- Initial treatment is 2000-3000 burns
- Spot size (200-500  $\mu\text{m}$ ) depends on contact lens magnification
- Gentle intensity burn (0.10-0.05 sec)
- Area covered by complete PRP
- Follow-up 4 to 8 weeks






# TREATMENT


---

- **LASER: Light Amplification by the Stimulated Emission of Radiation**
  - Focal
  - Grid
  - Panretinal photocoagulation




## Assessment after photocoagulation

### Poor involution




- Persistent neovascularization
- Hemorrhage
- Re-treatment required

### Good involution




- Regression of neovascularization
- Residual 'ghost' vessels or fibrous tissue
- Disc pallor

# Indications for vitreoretinal surgery



Severe persistent vitreous hemorrhage



Dense, persistent premacular hemorrhage




Progressive proliferation despite laser therapy




Retinal detachment involving macula

# Advanced diabetic eye disease

---




Preretinal fibrosis and tractional retinal detachment



Rubeosis iridis




# End-stage diabetic eye disease



## ➤ PHTHISIS

Shrunken, soft eye  
with

opaque vascularised  
cornea and no visual  
potential



# Overview

- **Background Information**
- **Retinal Vascular Disease**
- **Age-Related Macular Degeneration**
- **Diabetic Retinopathy**
- **Questions from the Audience**

# References

---

American Diabetes Association: Retinopathy in Diabetes (Position Statement). *Diabetes Care* 27 (Suppl.1): S84-S87, 2004

*Diabetic Retinopathy: What you should know.* Bethesda, MD: National Eye Institute, National Institutes of Health (NIH), DHHS; 2004.

Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, Klein R: Diabetic Retinopathy. *Diabetes Care* 21 (1): 143-156,1998.